Gorayski Peter, Burmeister Bryan, Foote Matthew
Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Future Oncol. 2015;11(3):525-34. doi: 10.2217/fon.14.300.
Cutaneous malignant melanoma remains a significant health burden worldwide despite advances in the management of locoregionally advanced and metastatic disease. Historically, the efficacy of radiation therapy (RT) has been questioned due to the perceived radioresistance of melanoma cancer cells in vitro. Nowadays, RT has limited indications for primary disease, but is used for high-risk nodal disease and in the palliative setting. This review article outlines the current role of RT for melanoma and its expanding role in oligometastatic disease scenarios as an alternative approach to surgery and highlights potential future applications to harness RT interaction with immunomodulatory targeted therapies.
尽管在局部晚期和转移性疾病的管理方面取得了进展，但皮肤恶性黑色素瘤在全球范围内仍然是一个重大的健康负担。从历史上看，由于在体外观察到黑色素瘤癌细胞具有放射抗性，放射治疗（RT）的疗效一直受到质疑。如今，RT在原发性疾病中的适应证有限，但用于高危淋巴结疾病和姑息治疗。这篇综述文章概述了RT在黑色素瘤治疗中的当前作用及其在寡转移疾病情况下作为手术替代方法的不断扩大的作用，并强调了RT与免疫调节靶向治疗相互作用的潜在未来应用。
